[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595702":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":51,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Takeda","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All Study Participants",null,"Data will be collected for participants with metastatic colorectal cancer (mCRC) who will receive Fruzaqla according to the approved indication as per the Physician's routine schedule.",[13],"Other: No intervention",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","No intervention","As this is an observational study, no intervention will be administered.",[9],[21],{"name":22,"affiliation":5,"role":23},"Study Director","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Takeda Contact","CONTACT","+1-877-825-3327","medinfoUS@takeda.com",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Yonsei University Hospital","RECRUITING","Seoul","03722","South Korea",{"type":38,"coordinates":39},"Point",[40,41],126.9784,37.566,{"lat":41,"lon":40},[44,48],{"name":45,"role":27,"phone":46,"phoneExt":10,"email":47},"Site Contact","82-10-3356-7610","BEOMSH@yuhs.ac",{"name":49,"role":50,"phone":10,"phoneExt":10,"email":10},"Beom Seung-Hoon","PRINCIPAL_INVESTIGATOR",{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100595702","a-study-to-monitor-the-fruzaqla-treatment-of-adults-with-metastatic-colorectal-cancer-mcrc-in-south-korea-100595702",false,"NCT07035886","A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea","Post-Marketing Surveillance (Usage Results Study) of Fruzaqla Capsule (Fruquintinib) for the Approved Indications in South Korea","Inclusion Criteria:\n\n* Age greater than or equal to (\\>=)18 years.\n* Participants who are initiate treatment or will be treated with Fruzaqla according to the approved label of South Korea.\n* Participant voluntarily consent to participate in the study.\n\nExclusion criteria:\n\n* Participants for whom Fruzaqla is contraindicated or those with risks that should avoid starting Fruzaqla, as per the product label.\n* Participants actively participating in other interventional clinical trial(s) on mCRC treatments.\n* Pregnant or breastfeeding women.","ALL","18 Years",{"count":63,"type":64},600,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.",[68],"Colorectal Cancer",[70,71,72],"Fruzaqla","Fruquintinib","Non-interventional","2026-02-26",{"date":75,"type":76},"2026-02-27","ACTUAL",{"date":78,"type":76},"2025-09-29",{"date":80,"type":64},"2031-03-01",{"name":5,"class":6},1]